SEBI barred Nirman Agri Genetics for diverting nearly 93% of IPO funds.
The firm’s shares hit a 5% lower circuit following the regulatory action.
SEBI found fictitious entities and false invoices in fund utilisation records.
The company’s promoter was restrained from trading, pending further investigation.